ESR2 and prostate carcinoma: The prevalence of ESR1 (which encodes ERα) and ESR2 (which encodes ERβ) mutations was 3% (5/150) in individuals with metastatic or advanced PCa, whereas it was 2% (11/492) in patients with early prostate cancer, according to a genomic dataset [63].